GENOMIC TESTING FOR
LUNG CANCER
Lung cancer is not one disease -- it is a collection of molecularly distinct diseases sharing a location. More than ten established targetable driver alterations have approved matched therapies. Comprehensive profiling before treatment starts is the only way to identify them.
Established Targetable Alterations in NSCLC
| Alteration | Frequency | Preferred Agent | Notes |
|---|---|---|---|
| EGFR mutations (exon 19 del / L858R) | 10-15% Western; up to 50% Asian | Osimertinib | First-line standard; CNS active; adjuvant approved post-resection |
| ALK fusions | 3-5% | Lorlatinib or alectinib | Lorlatinib covers most resistance mutations; both preferred over crizotinib |
| ROS1 fusions | ~1% | Entrectinib or repotrectinib | Entrectinib preferred for CNS activity |
| KRAS G12C | ~13% | Sotorasib or adagrasib | First approved KRAS inhibitors; historically undruggable mutation |
| MET exon 14 skipping | 3-4% | Capmatinib or tepotinib | More common in older patients and non-smokers |
| RET fusions | 1-2% | Selpercatinib or pralsetinib | Strong documented response rates; CNS active |
| BRAF V600E | 1-2% | Dabrafenib plus trametinib | BRAF/MEK combination as in melanoma |
| HER2 mutations (exon 20 insertion) | 2-3% | Trastuzumab deruxtecan (T-DXd) | Distinct from HER2 amplification; T-DXd approved for HER2-mutated NSCLC |
| NTRK fusions | Rare | Larotrectinib or entrectinib | Tumour-agnostic approval -- applies regardless of cancer type |
| PD-L1 expression | Assessed in all | Pembrolizumab (>=50%) | Guides immunotherapy in driver mutation-negative patients |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About Genomic Testing for Your Lung Cancer?
CancerFax reviews your NSCLC molecular results and connects you with specialist lung oncologists experienced in each approved targeted therapy.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.